Dynasty Biotechnology is pleased to announce commencement of a major partnership with Cambridge-based Nuformix in a long term, multi-product agreement.
The Nuformix biobetter products fit perfectly within the Dynasty portfolio of China-relevant assets to be developed and commercialised in China and rolled out to non-China markets. “We are delighted to be working with Nuformix and to come to agreement on the first set of assets,” commented Dynasty CEO Dr Simon Haworth. “We look forward to a long and fruitful partnership – between the Nuformix cocrystal technology and Dynasty’s China access and dedicated funding stream.”
Following market testing Dynasty Biotechnology is open for business and looks forward to engaging with other UK biotechs seeking access to this unique funding source. UK-based funding is now rare for development of products past the initial research phases, through to IND and beyond and Dynasty’s Chinese funding model opens up a whole new opportunity for the UK to use its world-leading innovation capability to address key global healthcare issues.
“Many have speculated about the potential for application of Chinese funding. Fortunately for UK biotech, we have now found a model that works for both sides” commented Dr Haworth.
Contact:
Dynasty Biotechnology is a Team Kapital investment: www.teamkapital.com
Dr Simon Haworth, Dynasty Biotechnology: simon.haworth@dynastybio.com 020 7060 4260
/ends
DEC